Skip to content

Assembly Biosciences ASMB Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$9.08M-$9.2M+9.8%-$10.2M-15.6%-$8.82M+14.7%
$26K-18.8%$32K0.0%$32K0.0%$32K-3.0%$33K+3.1%
$1.12M-23.6%$1.46M-12.5%$1.67M+100%$834K+17.1%$712K-5.2%
-$523K-944%$62K-93.2%$912K$0-$0
-$42K$940K$290K
-$5.09M-352%$2.02M-$4.56M-317%
$92K-95.7%$2.13M+148%$856K+143%-$2.01M-287%$1.08M
-$7.83M-9.1%-$7.17M+27.4%-$9.88M-2.6%-$9.63M-2.2%-$9.42M
-$22.1M-$15.13M+9.7%-$16.76M+28.5%-$23.44M-5,659%
$19K-20.8%$24K-42.9%$42K$0$0
$62.96M+445%$11.55M-93.6%$180.93M+934%$17.51M-11.8%$19.85M-51.5%
$57.6M+75.6%$32.8M+44.5%$22.7M-34.2%$34.5M+30.5%$26.43M-22.7%
-$5.38M-$158.27M-1,031%$16.99M+158%$6.59M
$0$1.92M-5.3%
$149K-67.3%$456K-99.7%$171.93M+48,060%$357K-81.4%$1.92M-88.7%
-$27.33M-176%$35.92M+2,540%-$1.47M-348%$593K+104%-$14.93M-251%
$7500.0%$7500.0%$7500.0%$750
-$849K$1.37M+429%-$415K-149%-$167K-124%
-$202K-3.6%-$195K+2.5%-$200K+4.8%-$210K-43.8%-$146K+58.6%
-$5.09M-352%$2.02M-$4.56M-317%
$92K-95.7%$2.13M+148%$856K+143%-$2.01M-287%$1.08M
$204K0.0%$204K-2.4%$209K-4.6%$219K0.0%$219K-38.0%
$57.6M+75.6%$32.8M+44.5%$22.7M-34.2%$34.5M+30.5%$26.43M-22.7%
$0$0$0$0-100%
$1.38M0.0%$1.38M0.0%$1.38M0.0%$1.38M
-$7.83M-9.1%-$7.17M+27.4%-$9.88M-2.6%-$9.63M-2.2%-$9.42M
-$22.12M-$15.18M+9.4%-$16.76M+28.5%-$23.44M-5,659%
-$22.12M-$15.18M+9.4%-$16.76M+28.5%-$23.44M-5,659%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Assembly Biosciences generate?
Assembly Biosciences (ASMB) generated -$77.4M in operating cash flow over the trailing twelve months.
What is Assembly Biosciences's free cash flow?
After $85.0K of capital expenditures, Assembly Biosciences's free cash flow was -$77.5M over the trailing twelve months, down 51.5% year over year.
Where does Assembly Biosciences's cash flow data come from?
Every line is extracted from Assembly Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.